LANSING, Mich., Jan. 3 /PRNewswire-FirstCall/ -- Neogen Corporation
(Nasdaq: NEOG) announced today that its net income for the second quarter of
FY 2008, which ended Nov. 30, increased 34% from the previous year's second
quarter. Adjusted for a 3-for-2 stock split, net income in the quarter rose to
$0.22 per share, compared to the prior year's $0.17. Neogen's second quarter
net income of $3,254,000 set another quarterly record for the 25-year-old
company.
Year-to-date net income for the first six months of Neogen's 2008 fiscal
year increased 30% to $6,265,000 from $4,832,000 in FY 2007, or to $0.42 per
share in the current year from the prior year's $0.34. Second quarter revenues
increased 23% to $27,210,000, also a quarterly record, compared to the prior
year's $22,189,000. Year-to-date revenues rose 18% during the fiscal year's
first half to $50,118,000 from FY 2007's $42,409,000.
The second quarter was the 59th consecutive profitable quarter from
operations for the company, and the 63rd quarter of the past 68 quarters to
show increased revenues as compared with the previous year.
"Those who have followed Neogen closely know of our goal to achieve $100
million in annual sales this year, and I'm pleased to report that we are half
way there after the first six months," said James Herbert, Neogen's chief
executive officer and chairman. "The quarter's revenue contributes to our
record of compound annual growth of 19% for the past 15 years."
Neogen's ongoing efforts to control costs, improve productivity, and the
results of economies of scale were evident in the second quarter. Operating
income as a percentage of sales increased to 17.6% in the current quarter from
the previous year's comparable quarter of 16.7%. On a six-month basis,
operating income is 18.6% of sales compared to 17.2% in the prior year.
"Looking ahead, the outlook for the rest of the fiscal year is
encouraging," said Lon Bohannon, Neogen's president and chief operating
officer. "Our Food Safety Division has strong momentum, and we have identified
numerous domestic and international sales opportunities to grow future sales.
New product introductions, and the successful integration of Kane Enterprise
products, have helped our Animal Safety Division's sales performance, and led
to the division posting significant sales increases over the prior year."
Neogen's Food Safety Division led the company's second quarter revenue
increase, with sales up 24% from $11,691,000 in FY 2007 to $14,474,000 in FY
2008. Year-to-date, the Food Safety Division's revenues were up 22% to
$28,232,000 for FY 2008. The division's growth was led by the third
consecutive quarter of outstanding growth (over 40%) in sales of the
Soleris(TM) general microbial detection system, a nearly 40% increase in sales
of its Acumedia(R) dehydrated culture media, and an increase in sales of dairy
antibiotic testing products.
Scotland-based Neogen Europe, Ltd., experienced another strong quarter,
with sales increasing 40% over FY 2007's second quarter. The sales increase
was led by sales of mycotoxin test kits, dehydrated culture media, and
Neogen's innovative AccuPoint(R) ATP Sanitation Monitoring System.
Neogen's Animal Safety Division second quarter revenues increased 21% to
$12,736,000, compared to $10,498,000 in the previous fiscal year. For FY
2008's first six months, the Animal Safety Division's sales increased 13% over
the comparable period last year to $21,886,000. While the August 2007 addition
of Kane Enterprise's animal health products contributed significantly to the
division's revenue gain, sales of existing products also experienced a solid
6% growth in the quarter.
Sales of OTC veterinary products increased 18% for the quarter. For the
first half of FY 2008, diagnostic product sales have increased 11%, with sales
of test kits to detect drugs of abuse in racing animals increasing 21% over
the prior year. Sales of rodenticides to international markets also achieved
strong growth over FY 2007's second quarter. Sales of Neogen's diphacinone
products into Mexico, and the expansion of product registrations in new
countries contributed to this success.
In December, Neogen announced that it had acquired the assets of Rivard
Instruments, Inc., of Winnipeg, Canada. Rivard Instruments and Neogen's
subsidiary, Ideal Instruments, Inc., are both manufacturers of detectable
veterinary hypodermic needles. The acquisition settles lengthy litigation
between the two companies regarding numerous patents owned by each.
Neogen's second quarter also saw Forbes Magazine name Neogen to its annual
list of the 200 Best Small Companies in America for the sixth time in eight
years. The Forbes list is based on growth in sales, earnings, and return on
equity for the past five years, and the latest 12 months.
Neogen Corporation develops and markets products dedicated to food and
animal safety. The company's Food Safety Division markets dehydrated culture
media, and diagnostic test kits to detect foodborne bacteria, natural toxins,
genetic modifications, food allergens, drug residues, plant diseases and
sanitation concerns. Neogen's Animal Safety Division markets a complete line
of diagnostics, veterinary instruments, veterinary pharmaceuticals,
nutritional supplements, disinfectants, and rodenticides.
Certain portions of this news release that do not relate to historical
financial information constitute forward-looking statements. These forward-
looking statements are subject to certain risks and uncertainties. Actual
future results and trends may differ materially from historical results or
those expected depending on a variety of factors listed in Management's
Discussion and Analysis of Financial Condition and Results of Operations in
the Company's most recently filed Form 10-K.
NEOGEN CORPORATION UNAUDITED SUMMARIZED CONSOLIDATED OPERATING DATA
(In thousands, except for per share and percentages)
Quarter ended Nov. 30 Six months ended Nov. 30
2007 2006 2007 2006
Revenue
Food Safety $14,474 $11,691 $28,232 $23,082
Animal Safety 12,736 10,498 21,886 19,327
Total revenue 27,210 22,189 50,118 42,409
Cost of sales 13,039 10,480 23,650 20,380
Gross margin 14,171 11,709 26,468 22,029
Other expenses
Sales & marketing 5,456 4,665 10,134 8,905
Administrative 2,862 2,333 5,192 4,137
Research &
development 1,055 1,015 1,797 1,713
Total other expenses 9,373 8,013 17,123 14,755
Operating income 4,798 3,696 9,345 7,274
Other income/expense 306 5 470 59
Income before tax 5,104 3,701 9,815 7,333
Income tax 1,850 1,275 3,550 2,501
Net income $3,254 $2,426 $6,265 $4,832
Net income per
diluted share(1) $0.22 $0.17 $0.42 $0.34
Other information:
Shares to calculate
per share(1) 14,846 14,129 14,816 14,039
Depreciation &
amortization $862 $781 $1,670 $1,558
Interest expense - - - 11
Gross margin
(% of sales) 52.1% 52.8% 52.8% 51.9%
Operating income
(% of sales) 17.6% 16.7% 18.6% 17.2%
Revenue increase
vs. FY 2007 22.6% 18.2%
Net income increase
vs. FY 2007 34.1% 29.7%
NEOGEN CORPORATION UNAUDITED SUMMARIZED CONSOLIDATED BALANCE SHEET DATA
(In thousands)
Nov. 30 May 31
2007 2007
Assets
Current assets
Cash & cash equivalents $10,415 $13,424
Accounts receivable 19,357 14,914
Inventory 23,142 19,116
Other current assets 3,710 3,644
Total current assets 56,624 51,098
Property & equipment 16,501 16,402
Goodwill & other assets 41,803 37,784
Total assets $114,928 $105,284
Liabilities & Stockholders' Equity
Current liabilities $10,174 $10,038
Long-term lines of credit - -
Other long-term liabilities 3,080 3,301
Stockholders' equity-shares outstanding
14,328 in Nov. & 14,020 in May(1) 101,674 91,945
Total liabilities & stockholders'
equity $114,928 $105,284
(1) Reflects effect of Sept. 4, 2007, 3-for-2 stock split
SOURCE Neogen Corporation
Richard R. Current, Vice President and CFO, Neogen Corporation,
+1-517-372-9200
